Latest Novartis Group Stories
-- In Quebec alone 386,000 people suffer from COPD and it is the fourth leading cause of death in Canada.
With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide BASEL, Switzerland, Jan.
-- Fourth indication for injection treatment that can stabilize and improve vision(1) -- mCNV a leading cause of visual impairment among those 20-50 years of age(9) Since
-- Today is the first ever International Urticaria Day, an international event to increase urticaria awareness and improve care around the globe and let people living with urticaria
-- LANTERN study met primary endpoint demonstrating non-inferiority of Ultibro® Breezhaler® 110/50 mcg vs Advair* Diskus* (SFC) 50/500 mcg followed by statistically
-- LCZ696 mortality benefit exceeded what was achieved with enalapril, an ACE-inhibitor, when replacing enalapril combined with current treatment
Submission follows receipt of Breakthrough Therapy designation in April 2014, highlighting unmet need for a licensed vaccine for serogroup B in the US(1) BASEL, Switzerland, June 17, 2014 /PRNewswire/
Cell-culture technology is a modern alternative to manufacture influenza vaccines without chicken eggs, with potential to rapidly respond to a pandemic BASEL, Switzerland, June 16, 2014
DORVAL QC, Feb.
- FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada CAMBRIDGE, Mass., Feb.